Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
复制标题
DOI：
10.1007/s10067-020-05490-w
复制
发表时间：
2021-05
影响因子：
3.4
通讯作者：
Karagülle M
中科院分区：
文献类型：
--
作者：
Kardeş S;Kuzu AS;Pakhchanian H;Raiker R;Karagülle M
公众可以通过搜索引擎利用在线信息了解一些抗风湿药物的影响和风险。这些药物已用于管理2019冠状病毒病（COVID-19）和相关的炎症后遗症或感染的细胞因子风暴。因此，本研究的目的是通过分析谷歌搜索频率数据的变化，调查COVID-19时代人群对抗风湿药物的兴趣。为了获得抗风湿药物的相对搜索量（RSV），我们查询了Google趋势，以获得代表美国境内非甾体抗炎药（NSAID）、糖皮质激素、抗痛风药、常规疾病缓解抗风湿药（DMARD）、免疫抑制剂、生物制剂和Janus激酶（JAK）抑制剂的78个搜索词。2020年的三个8周期间（3月15日至5月9日），（5月10日至7月4日）和（7月5日至8月29日）代表初始和短期期间，与前三年（2017-2019）的重叠期间进行了比较。我们发现秋水仙碱、羟氯喹、托珠单抗（及其商品名-Actemra）和阿那白滞素的RSV在统计学上显著增加，而免疫抑制剂的商品名（即，与前3年的重叠期相比，在初始和短期COVID-19期间，使用吗替麦考酚酯、硫唑嘌呤、环磷酰胺、他克莫司、环孢霉素）。与之前3年的重叠期相比，在COVID-19初期和短期期间，秋水仙碱、羟氯喹、托珠单抗和阿那白滞素的RSV显著增加，反映了大流行期间对这些药物的信息寻求水平提高。修辞学家应该解决这种信息需求的增加。需要进一步研究评估抗风湿药物的中期和长期利益，以增加我们对这一新的流行病的认识。
The general public may utilize online information through search engines for implications and risks of some anti-rheumatic drugs. These drugs have been used in the management of coronavirus disease 2019 (COVID-19) and associated inflammatory sequelae or cytokine storm of infection. Therefore, the objective of this study was to investigate the population-level interest in anti-rheumatic drugs during the COVID-19 era, by analyzing changes in Google search frequency data. To obtain the relative search volume (RSV) of anti-rheumatic drugs, we queried Google Trends for 78 search terms representing non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, antigout agents, conventional disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, biologics, and Janus kinase (JAK) inhibitors within the USA. Three 8-week periods in 2020 (March 15–May 9), (May 10–July 4), and (July 5–August 29) representing the initial- and short-term periods were compared to overlapping periods of the preceding 3 years (2017–2019). We found statistically significant increases in RSV for colchicine, hydroxychloroquine, tocilizumab (and its brand name-Actemra), and anakinra, and statistically significant decreases among brand names of immunosuppressive agents (i.e., mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine) during both the initial- and short-term COVID-19 periods as compared to overlapping periods of the preceding 3 years. There were significant increases in RSV of colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial- and short-term COVID-19 periods when compared to overlapping periods of the preceding 3 years reflecting a heightened level of information-seeking on these drugs during the pandemic. Rheumatologists should address this increase in informational demand. Further research assessing medium- and long-term interest in anti-rheumatic drugs is required to increase our knowledge on this new pandemic.
登录
查看更多内容
影响因子：
8.5
作者：
Mavragani, Amaryllis;Ochoa, Gabriela
通讯作者：
Ochoa, Gabriela
影响因子：
4
作者：
Montero, Fernando;Martinez-Barrio, Julia;alvaro-Gracia, Jose
通讯作者：
alvaro-Gracia, Jose
影响因子：
3
作者：
Kardes, Sinan
通讯作者：
Kardes, Sinan
影响因子：
3.5
作者：
Jella, Tarun K.;Samuel, Linsen T.;Kamath, Atul F.
通讯作者：
Kamath, Atul F.
影响因子：
3.4
作者：
Misra, Durga Prasanna;Agarwal, Vikas;Zimba, Olena
通讯作者：
Zimba, Olena